The biopharmaceutical company ‘Biofarma’(Biopharma) plans to launch a plant in Arad (Romania) at the end of 2027, with an initial investment of EUR85 million, the company’s president, Konstantin Efimenko, told the Interfax-Ukraine news agency.
“We have already completed construction of the building and will have finished installing all the utilities by 1 September. We have already ordered the filling line. By the end of June, we will have contracted for the reactor equipment and all other process equipment. We will commence operations in December 2027,” said Yefimenko.
The initial investment in the Arad plant is EUR85 million; the Romanian project as a whole will comprise four phases of varying sizes. Total investment in the plants in Uzhhorod and Arad amounts to approximately $500 million.
He noted that the company’s development is not focused on a single project.
“Bila Tserkva is our flagship plant. We are not shifting our focus, but are developing everything — both Uzhhorod and Arad — and we will go on to build in Latin America,” said Yefimenko.
As previously reported, Biopharma plans to launch the first phase of its plant for the production of pharmaceutical products and immunobiological preparations in Uzhhorod in September 2026, which will provide a full cycle of blood plasma processing. The company has already invested EUR67 million in the construction, with the total cost of the first phase amounting to EUR75 million. According to the plan, the volume of blood plasma-derived medicines produced in Uzhhorod will be double that of Bila Tserkva, amounting to up to 1.5 million litres of blood plasma per year; the project in Romania is set to be twice as large.
During the ‘Industrial Evolution: Manufacturing Drives the Economy’ forum in Bila Tserkva, Yefimenko also announced that Biopharma had registered its albumin product in Brazil.
Biopharma exports its products to dozens of countries and plans to expand its presence in Europe, the Middle East and Latin America, whilst continuing to grow its capabilities.